Personalized vaccine for high-risk endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk, recurrent, or advanced endometrial cancer that cannot be removed by surgery or cured by radiation.
- Your tumor can be seen on scans (CT or MRI), and you have enough tumor tissue (from a recent biopsy or surgery) to make the vaccine.
- You have not had chemotherapy for at least 3 weeks, or other cancer treatments for at least 2 to 4 weeks before starting the vaccine.
- You are well enough to receive cancer therapy (ECOG performance status 0 or 1) and expected to live at least 3 months.
- Your blood counts and liver/kidney function are within acceptable ranges, and you have no uncontrolled infections or unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
This trial tests a personalized approach to treating advanced ovarian or endometrial cancers that have come back or stopped responding to standard treatments. It uses a special model to guide which therapy might work best for you.
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
This trial tests a personalized vaccine made from your own immune cells and tumor mutations. It's for people with HRD-negative ovarian cancer who still have signs of cancer after standard treatment.
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
Hear when a new Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.